Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Vaccines

Free Subscription Articles published in Clin Infect Dis Retrieve available abstracts of 108 articles: HTML format

Single Articles

October 2025
1. BELSHE RB, Bernstein DI, Edwards KM, Frey SE, et al
   Vaccine and Treatment Evaluation Units: A Historical Perspective.
   Clin Infect Dis. 2025;81.
   PubMed     Abstract available
   
   
   
2. JANO K, Babu TM, Kottkamp AC, Rebolledo PA, et al
   Historical Advances in Clinical Trial Design and Expanding Representation as the New Frontier for Innovation.
   Clin Infect Dis. 2025;81.
   PubMed     Abstract available
   
   
   
3. DOBRZYNSKI DM, Graciaa DS, Babu TM, Coler RN, et al
   From Yesterday to Tomorrow: How Vaccine Platforms Have Shaped the Vaccine and Treatment Evaluation Units.
   Clin Infect Dis. 2025;81.
   PubMed    
   
   
   
4. WHITAKER JA, Collins MH, Rebolledo PA, Dobrzynski D, et al
   Future Goals and Long-term Vision of the Infectious Diseases Clinical Research Consortium/Vaccine and Treatment Evaluation Unit Network.
   Clin Infect Dis. 2025;81.
   PubMed     Abstract available
   
   
   
5. ATMAR RL, Abate G, Deming ME, George SL, et al
   Emerging and Pandemic Pathogens: Lessons Learned From a Clinical Research Network.
   Clin Infect Dis. 2025;81.
   PubMed     Abstract available
   
   
   
6. ERBELDING EJ, Marrazzo JM
   Vaccine Treatment and Evaluation Units: Why Support a "Ready Base" of Clinical Trial Sites?
   Clin Infect Dis. 2025;81.
   PubMed     Abstract available
   
   
   
7. BELONGIA EA, Nguyen HQ, McClure DL, Lewis N, et al
   Approaches to Comparing Influenza Vaccine Effectiveness to Guide Potential Preferential Product Recommendations.
   Clin Infect Dis. 2025 Oct 9:ciaf563. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. STAFFORD E, Dimitrov D, Trinidad SB, Matrajt L, et al
   Closing the Gap in Race-based Inequities for Seasonal Influenza Hospitalizations: A Modeling Study.
   Clin Infect Dis. 2025;81:478-487.
   PubMed     Abstract available
   
   
   September 2025
9. CARAZO S, Phimmasone J, Skowronski DM, Giguere K, et al
   Effectiveness of COVID-19 vaccination and prior infections to reduce long COVID risk during the pre-Omicron and Omicron periods.
   Clin Infect Dis. 2025 Sep 29:ciaf549. doi: 10.1093.
   PubMed     Abstract available
   
   
   
10. GOSWAMI J, Cardona JF, Caso J, Hsu DC, et al
    Safety, Tolerability, and Immunogenicity of Revaccination with mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged >/=50 Years.
    Clin Infect Dis. 2025 Sep 23:ciaf515. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. COLOMBO RE, Richard SA, Schmidt K, Schofield C, et al
    Randomized pragmatic trial of the comparative effectiveness of chicken egg-based inactivated, mammalian cell-culture-based inactivated, and recombinant protein quadrivalent seasonal influenza vaccines in United States Military Health System beneficiar
    Clin Infect Dis. 2025 Sep 18:ciaf503. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. SHETTY AN, Hennessy D, Kattan GS, Ojaimi S, et al
    Transient increased risk of shingles post Shingrix vaccination: Self-controlled case series analysis.
    Clin Infect Dis. 2025 Sep 9:ciaf473. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. GODIN A, Brickley EB, Connor RI, Wieland-Alter WF, et al
    Intestinal mucosal immune responses to novel oral poliovirus vaccine type 2 in healthy newborns.
    Clin Infect Dis. 2025 Sep 5:ciaf484. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2025
14. REZAHOSSEINI O, Staehr Jensen JU, Rahimi HK, Jensen NE, et al
    Immunogenicity and Safety of the COVID-19 mRNA Vaccine Coadministered with Influenza and 23-valent Pneumococcal Polysaccharide Vaccines.
    Clin Infect Dis. 2025 Aug 18:ciaf455. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. RAYENS E, Sy LS, Qian L, Wu J, et al
    Adjuvanted recombinant zoster vaccine is effective against herpes zoster ophthalmicus, and is associated with lower risk of acute myocardial infarction and stroke in adults aged >/=50 years.
    Clin Infect Dis. 2025 Aug 9:ciaf440. doi: 10.1093.
    PubMed     Abstract available
    
    
    
16. RON R, Diaz-Garcia C, Sendagorta E, Cabello-Ubeda A, et al
    A Phase IV, open-label, single-arm, multicentric clinical trial for evaluation of Human Papillomavirus 9vHPV vaccine immunogenicity in Men Who Have Sex with Men living with HIV: GeSIDA Study 10017.
    Clin Infect Dis. 2025 Aug 6:ciaf435. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. SCHNYDER JL, Haggenburg S, Garcia Garrido HM, Reiners A, et al
    Long-term immunogenicity and boostability of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in adults receiving immunosuppressive therapy and adults living with HIV - 3-year follow-up of a pr
    Clin Infect Dis. 2025 Aug 6:ciaf438. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2025
18. PARRA G, Lessa FC, Campelo E, Amorim Ramos TC, et al
    Incidence of and Risk Factors for SARS-CoV-2 Infection Among Vaccinated Healthcare Workers During Emergence of SARS-CoV-2 Gamma Variant in the Amazon Region, Brazil, 2021.
    Clin Infect Dis. 2025 Jul 30:ciaf339. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. HUNDIE GB, Ashengo TA, Stender SC, Abraha M, et al
    Assessing Coronavirus Disease 2019 Vaccination Uptake and Incident Infections Among Ethiopian Healthcare Workers, Addis Ababa-2022: Implications for Public Health Preparedness.
    Clin Infect Dis. 2025 Jul 29:ciaf341. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. PONCE D, Westercamp M, Soto G, Lessa FC, et al
    COVID-19 Exposure, Protective Measures, Symptom Assessment, and Risk Perception Among Healthcare Workers in Peru: A Longitudinal Cohort Study (2020-2021).
    Clin Infect Dis. 2025 Jul 29:ciaf343. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. CHISSUMBA RM, Kwatra G, Ramgi P, Enosse M, et al
    Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine.
    Clin Infect Dis. 2025;80.
    PubMed     Abstract available
    
    
    
22. KANG SSY, Tadesse BT, Jeon HJ, Fallah MP, et al
    Enhancing Clinical Trial Sites in Low- and Middle-Income Countries to Facilitate Product Development in Response to the COVID-19 Pandemic.
    Clin Infect Dis. 2025;80.
    PubMed     Abstract available
    
    
    
23. KIM CL, Thwe TT, Espinoza LMC, Sugimoto JD, et al
    Overcoming Vaccine Inequities and Research Gaps in Africa: Challenges and Opportunities Identified During the COVID-19 Pandemic.
    Clin Infect Dis. 2025;80.
    PubMed     Abstract available
    
    
    
24. RAMGI P, Siribie M, Rakotozandrindrainy N, Bule O, et al
    Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique.
    Clin Infect Dis. 2025;80.
    PubMed     Abstract available
    
    
    
25. CAPITINE IU, Aziz AB, Manhica A, Tivane I, et al
    Real-world Evaluation of the Effectiveness of Sinopharm COVID-19 Vaccine Against Symptomatic COVID-19 in an Omicron-Dominant Setting in Mozambique: A Test-Negative, Case-Control Study.
    Clin Infect Dis. 2025;80.
    PubMed     Abstract available
    
    
    
26. DE SCHACHT C, Capitine IU, Lucas C, Muteerwa A, et al
    Importance of Targeted Communication Strategies During COVID-19 Vaccination Campaigns in Mozambique: Results of a Mixed-Methods Acceptability Study.
    Clin Infect Dis. 2025;80.
    PubMed     Abstract available
    
    
    
27. SIZA C, Plucinski M, Lessa FC, Campelo E, et al
    Antibody Response in Healthcare Workers During the Severe Acute Respiratory Syndrome Coronavirus 2 Gamma Variant Outbreak in Manaus, Brazil.
    Clin Infect Dis. 2025 Jul 16:ciaf318. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. MANNING JE, Beckers F, de Bruijn I, Sridhar S, et al
    First Among Equals: The Case for High-quality Clinical Data in Influenza Vaccines.
    Clin Infect Dis. 2025 Jul 15:ciaf290. doi: 10.1093.
    PubMed    
    
    
    
29. WANG B, Giles L, Andraweera P, McMillan M, et al
    Long-term protection against invasive meningococcal B disease and gonococcal infection five years after implementation of funded childhood and adolescent 4CMenB vaccination program in South Australia: an observational cohort and case-control study.
    Clin Infect Dis. 2025 Jul 10:ciaf372. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2025
30. TSENG HF, Sy LS, Ackerson BK, Rayens E, et al
    Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Adults >/=50 Years in the United States.
    Clin Infect Dis. 2025 Jun 23:ciaf329. doi: 10.1093.
    PubMed     Abstract available
    
    
    
31. XHAFERI A, Bino S, Daja R, Vasili A, et al
    Sociodemographic and Occupational Factors Associated With Coronavirus Disease 2019 Vaccine and Influenza Vaccine Uptake Among Healthcare Workers, in Albania, 2022-2023: A Multicenter Study.
    Clin Infect Dis. 2025 Jun 3:ciaf202. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2025
32. CHUMAKOV K, Plotkin SA
    Inactivated Polio Vaccine Must Be an Essential Part of Polio Eradication.
    Clin Infect Dis. 2025 May 21:ciaf215. doi: 10.1093.
    PubMed    
    
    
    
33. MEHMOOD N, Alam MM, Arshad Y, Akhtar R, et al
    Clinical and Epidemiological Investigation of Vaccine-Derived Poliovirus Type 2 Outbreak in Pakistan During 2019-2021.
    Clin Infect Dis. 2025 May 21:ciaf151. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. KU JH, Gu YM, Hoke CF, Tseng HF, et al
    Screening and vaccination rates for tetanus, hepatitis A, and hepatitis B among individuals with substance use disorders who are hospitalized in an integrated U.S. health system.
    Clin Infect Dis. 2025 May 20:ciaf251. doi: 10.1093.
    PubMed     Abstract available
    
    
    
35. REGAN JJ, Wang Z, Phares CR
    The Effect of Live-Virus Vaccines on Tests for Tuberculosis Infection During the US Immigration Medical Examination: Are Vaccines Causing False-Negative Results?
    Clin Infect Dis. 2025 May 15:ciaf129. doi: 10.1093.
    PubMed     Abstract available
    
    
    
36. KONOPNICKI D, Gilles C, Manigart Y, Barlow P, et al
    Immunogenicity and safety of two versus three doses of 9-valent vaccine against Human papillomavirus (HPV) in women with HIV: the Papillon randomized trial.
    Clin Infect Dis. 2025 May 13:ciaf241. doi: 10.1093.
    PubMed     Abstract available
    
    
    
37. AMARIN JZ, Toepfer AP, Spieker AJ, Hayek H, et al
    Respiratory Syncytial Virus Co-Detection With Other Respiratory Viruses Is Not Significantly Associated With Worse Clinical Outcomes Among Children Aged <2 Years: New Vaccine Surveillance Network, 2016-2020.
    Clin Infect Dis. 2025 May 9:ciaf194. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2025
38. TORCEL-PAGNON L, Coudeville L, Harris RC, Chaves SS, et al
    The Impact of Influenza on US Working-Age Adults: Exploring the Benefits of the Recombinant Influenza Vaccine.
    Clin Infect Dis. 2025 Apr 17:ciaf200. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. MESSCHENDORP AL, Zaeck LM, Bouwmans P, van den Broek DAJ, et al
    Replacing Mycophenolate Mofetil by Everolimus in Kidney Transplant Recipients to Increase Vaccine Immunogenicity: Results of a Randomized Controlled Trial.
    Clin Infect Dis. 2025 Apr 15:ciaf107. doi: 10.1093.
    PubMed     Abstract available
    
    
    
40. IOANNOU GN, Berry K, Rajeevan N, Li Y, et al
    Target Trial Emulation of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus No Infection and Risk of Post-Coronavirus Disease 2019 Conditions in the Omicron Variant Versus Prior Eras.
    Clin Infect Dis. 2025 Apr 10:ciaf087. doi: 10.1093.
    PubMed     Abstract available
    
    
    
41. FOX A, Sanchez-Ovando S, Carolan L, Hadiprodjo AJ, et al
    Enhanced Influenza Vaccines Extend A(H3N2) Antibody Reactivity in Older Adults but Prior Vaccination Effects Persist.
    Clin Infect Dis. 2025 Apr 3:ciaf060. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2025
42. KELLY JD, Hoggatt KJ, Lo NC, Leonard S, et al
    Annual variant-targeted vaccination to prevent severe COVID-19 disease in cohorts with vaccine-derived and hybrid immunity.
    Clin Infect Dis. 2025 Mar 14:ciaf124. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2025
43. DAVIDO B, Kharkhordine M
    Enhancing Influenza Vaccination for Adults Aged 50-64: Addressing Moderate Vaccine Efficacy.
    Clin Infect Dis. 2025 Feb 20:ciaf070. doi: 10.1093.
    PubMed    
    
    
    
44. WALSH EE, Eiras D, Woodside J, Jiang Q, et al
    Efficacy, Immunogenicity, and Safety of the Bivalent RSV Prefusion F (RSVpreF) Vaccine in Older Adults Over 2 RSV Seasons.
    Clin Infect Dis. 2025 Feb 10:ciaf061. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2025
45. BANOONI P, Gonik B, Epalza C, Reyes O, et al
    Efficacy, immunogenicity, and safety of an investigational maternal respiratory syncytial virus prefusion F protein-based vaccine.
    Clin Infect Dis. 2025 Jan 29:ciaf033. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. 
    Correction to: Incidence of Tetanus and Diphtheria in Relation to Adult Vaccination Schedules.
    Clin Infect Dis. 2025 Jan 15:ciaf014. doi: 10.1093.
    PubMed    
    
    
    
47. CHUNG JR, Price AM, Zimmerman RK, Moehling Geffel K, et al
    Influenza vaccine effectiveness against medically attended outpatient illness, United States, 2023-24 season.
    Clin Infect Dis. 2025 Jan 6:ciae658. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2024
48. BIRABAHARAN M, Johns ST, Kaelber DC, Martin TCS, et al
    Atrial Fibrillation after RSV Vaccination Among Older Adults.
    Clin Infect Dis. 2024 Dec 26:ciae649. doi: 10.1093.
    PubMed     Abstract available
    
    
    
49. NOLAN T, Bhusal C, Hoberman A, Llapur CJ, et al
    Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults who had Previously Received a Meningococcal ACWY Vaccine: Phase 3, Randomized, Controlled Clinical Study.
    Clin Infect Dis. 2024 Dec 26:ciae622. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. PLOTKIN SA, Shapiro ED
    The Current and Future State of Vaccines for Lyme Disease.
    Clin Infect Dis. 2024 Dec 23:ciae639. doi: 10.1093.
    PubMed     Abstract available
    
    
    
51. WANG X, Patel C, Giles ML, Burns P, et al
    Glucocorticoid dosing and implications for vaccination: Evolution of global definitions.
    Clin Infect Dis. 2024 Dec 18:ciae613. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. DAGAN R, van der Beek BA
    Immune Response to the 13-Valent Pneumococcal Conjugate Vaccine is Reduced in Infants Immunized during the Respiratory Viral Season.
    Clin Infect Dis. 2024 Dec 17:ciae619. doi: 10.1093.
    PubMed     Abstract available
    
    
    
53. WEE LE, Lim JT, Goel M, Malek MIA, et al
    Bivalent boosters and risk of post-acute sequelae following vaccine-breakthrough SARS-CoV-2 Omicron infection: a cohort study.
    Clin Infect Dis. 2024 Dec 5:ciae598. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. TENFORDE MW, Reeves EL, Weber ZA, Tartof SY, et al
    Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023-2024 season, United States.
    Clin Infect Dis. 2024 Dec 4:ciae597. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2024
55. TOWNSEND JP, Hassler HB, Dornburg A
    Optimal Annual COVID-19 Vaccine Boosting Dates Following Previous Booster Vaccination or Breakthrough Infection.
    Clin Infect Dis. 2024 Nov 26:ciae559. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. CHOKEPHAIBULKIT K, Huoi C, Tantawichien T, Mootsikapun P, et al
    Non-inferiority study of purified Vero rabies vaccine - serum free in three-dose and two-dose pre-exposure prophylaxis regimens in comparison with licensed rabies vaccines.
    Clin Infect Dis. 2024 Nov 26:ciae581. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. 
    Correction to: Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age Group.
    Clin Infect Dis. 2024 Nov 15:ciae504. doi: 10.1093.
    PubMed    
    
    
    
58. 
    Correction to: Development of an Effective Immune Response in Adults With Down Syndrome After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination.
    Clin Infect Dis. 2024 Nov 15:ciae506. doi: 10.1093.
    PubMed    
    
    
    
59. DAVIS M, Towner W, DeHaan E, Jiang Q, et al
    Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions.
    Clin Infect Dis. 2024 Nov 11:ciae550. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. ROGERS JH, Westley B, Mego T, Newell KG, et al
    Fatal borealpox in an immunosuppressed patient treated with antivirals and vaccinia immunoglobulin - Alaska, 2023.
    Clin Infect Dis. 2024 Nov 5:ciae536. doi: 10.1093.
    PubMed     Abstract available
    
    
    
61. VAN DER STAAK M, Ten Hulscher HI, Nicolaie AM, Smits GP, et al
    Long-term dynamics of measles virus-specific neutralizing antibodies in children vaccinated before 12 months of age.
    Clin Infect Dis. 2024 Nov 4:ciae537. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2024
62. WHITE EB, Grant L, Mak J, Olsho L, et al
    Influenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in 2022-2023: A Prospective Cohort Study.
    Clin Infect Dis. 2024 Oct 24:ciae491. doi: 10.1093.
    PubMed     Abstract available
    
    
    
63. TAN SK, Cebrik D, Plotnik D, Agostini ML, et al
    A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA).
    Clin Infect Dis. 2024;79:1054-1061.
    PubMed     Abstract available
    
    
    
64. SELF WH, Johnson KD, Resser JJ, Whitney CG, et al
    Prevalence, Clinical Severity, and Serotype Distribution of Pneumococcal Pneumonia Among Adults Hospitalized With Community-Acquired Pneumonia in Tennessee and Georgia, 2018-2022.
    Clin Infect Dis. 2024;79:838-847.
    PubMed     Abstract available
    
    
    
65. BEGLEY KM, Leis AM, Petrie JG, Truscon R, et al
    Epidemiology of Respiratory Syncytial Virus in Adults and Children With Medically Attended Acute Respiratory Illness Over Three Seasons.
    Clin Infect Dis. 2024;79:1039-1045.
    PubMed     Abstract available
    
    
    
66. MONTANO M, Shapiro AE, Whitney BM, Bamford L, et al
    Mpox in People With Human Immunodeficiency Virus: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort.
    Clin Infect Dis. 2024 Oct 8:ciae464. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2024
67. FONG Y, Dang L, Zhang B, Fintzi J, et al
    Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
    Clin Infect Dis. 2024 Sep 26:ciae465. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. LEUNG J, Munir NA, Mathis AD, Filardo TD, et al
    The Effects of Vaccination Status and Age on Clinical Characteristics and Severity of Measles Cases in the United States in the Post-Elimination Era, 2001-2022.
    Clin Infect Dis. 2024 Sep 13:ciae470. doi: 10.1093.
    PubMed     Abstract available
    
    
    
69. PLOTKIN SA, Robinson JM, Fitchett JRA, Gershburg E, et al
    Vaccine Development Should Be Polytheistic, Not Monotheistic.
    Clin Infect Dis. 2024 Sep 6:ciae460. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2024
70. 
    Correction to: Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged >/=18 Years.
    Clin Infect Dis. 2024 Aug 29:ciae389. doi: 10.1093.
    PubMed    
    
    
    
71. 
    Correction to: Immunogenicity and Safety of a Purified Vero Rabies Vaccine-Serum Free, Compared With 2 Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized, Controlled, Phase 3 Trial.
    Clin Infect Dis. 2024 Aug 28:ciae390. doi: 10.1093.
    PubMed    
    
    
    
72. DONSKEY CJ, Dubberke ER, Klein NP, Liles EG, et al
    CLOVER: A Phase 3 Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection.
    Clin Infect Dis. 2024 Aug 24:ciae410. doi: 10.1093.
    PubMed     Abstract available
    
    
    
73. KUIJPER EJ, Gerding DN
    The end of toxoid vaccine development for preventing Clostridioides difficile infections?
    Clin Infect Dis. 2024 Aug 24:ciae412. doi: 10.1093.
    PubMed    
    
    
    
74. KU JH, Rayens E, Sy LS, Qian L, et al
    Comparative Effectiveness of Licensed Influenza Vaccines in Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022-2023 Influenza Season Among Adults >/=65 Years of Age.
    Clin Infect Dis. 2024 Aug 21:ciae375. doi: 10.1093.
    PubMed     Abstract available
    
    
    
75. BERTHAUD V, Creech CB, Rostad CA, Carr Q, et al
    Safety and Immunogenicity of an mRNA-1273 Booster in Children.
    Clin Infect Dis. 2024 Aug 19:ciae420. doi: 10.1093.
    PubMed     Abstract available
    
    
    
76. JAYASINGHE S, Williams PCM, Macartney KK, Crawford NW, et al
    Assessing the Impact of Pneumococcal Conjugate Vaccine Immunization Schedule Change From 3+0 to 2+1 in Australian Children: A Retrospective Observational Study.
    Clin Infect Dis. 2024 Aug 14:ciae377. doi: 10.1093.
    PubMed     Abstract available
    
    
    
77. MA KC, Surie D, Lauring AS, Martin ET, et al
    Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024.
    Clin Infect Dis. 2024 Aug 6:ciae405. doi: 10.1093.
    PubMed     Abstract available
    
    
    
78. FERGUSON M, Schwarz TF, Nunez SA, Rodriguez-Garcia J, et al
    Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to >/=60 Years of Age.
    Clin Infect Dis. 2024 Aug 5:ciae364. doi: 10.1093.
    PubMed     Abstract available
    
    
    
79. CLARK R, Davies S, Labrador J, Loubet P, et al
    Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial.
    Clin Infect Dis. 2024 Aug 5:ciae365. doi: 10.1093.
    PubMed     Abstract available
    
    
    
80. BRANCHE AR
    We Have Effective Respiratory Syncytial Virus Vaccines to Prevent Disease in Adults: What Else Do We Need to Know About How to Use Them?
    Clin Infect Dis. 2024 Aug 5:ciae362. doi: 10.1093.
    PubMed    
    
    
    July 2024
81. SCOTT P, Haranaka M, Choi JH, Stacey H, et al
    A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older (Stride-6).
    Clin Infect Dis. 2024 Jul 31:ciae383. doi: 10.1093.
    PubMed     Abstract available
    
    
    
82. COWLING BJ, Wong SS, Santos JJS, Touyon L, et al
    Preliminary findings from the Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE I) Study: a Randomized Controlled Trial.
    Clin Infect Dis. 2024 Jul 23:ciae380. doi: 10.1093.
    PubMed     Abstract available
    
    
    
83. EDOSA M, Jeon Y, Gedefaw A, Hailu D, et al
    Comprehensive Review on the Use of Oral Cholera Vaccine (OCV) in Ethiopia: 2019 to 2023.
    Clin Infect Dis. 2024;79.
    PubMed     Abstract available
    
    
    
84. HUSSEN M, Worku Demlie Y, Edosa M, Kebede M, et al
    Ethiopia National Cholera Elimination Plan 2022-2028: Experiences, Challenges, and the Way Forward.
    Clin Infect Dis. 2024;79.
    PubMed     Abstract available
    
    
    
85. PARK SE, Gedefaw A, Hailu D, Jeon Y, et al
    Coverage of Two-Dose Preemptive Cholera Mass Vaccination Campaign in High-Priority Hotspots in Shashemene, Oromia Region, Ethiopia.
    Clin Infect Dis. 2024;79.
    PubMed     Abstract available
    
    
    
86. BORJA-TABORA C, Fernando L, Lopez Medina E, Reynales H, et al
    Immunogenicity, safety, and efficacy of a tetravalent dengue vaccine in children and adolescents: an analysis by age group.
    Clin Infect Dis. 2024 Jul 12:ciae369. doi: 10.1093.
    PubMed     Abstract available
    
    
    
87. JOHNSTON TS, Hage C, Abedon AT, Panda S, et al
    Rapid Wane and Recovery of XBB Sublineage Neutralization After Sequential Omicron-based Vaccination in Solid Organ Transplant Recipients.
    Clin Infect Dis. 2024 Jul 2:ciae279. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2024
88. CHONG C, Wee LE, Jin X, Zhang M, et al
    Risks of SARS-CoV-2 JN.1 infection and COVID-19 associated emergency-department (ED) visits/hospitalizations following updated boosters and prior infection: a population-based cohort study.
    Clin Infect Dis. 2024 Jun 26:ciae339. doi: 10.1093.
    PubMed     Abstract available
    
    
    
89. RUSS RK, Vandehei HM, Golovkina MI, Mogallapalli H, et al
    Hepatitis B-CpG vaccine series for healthcare workers who are hepatitis B vaccine nonresponders.
    Clin Infect Dis. 2024 Jun 17:ciae320. doi: 10.1093.
    PubMed     Abstract available
    
    
    
90. BOECKH M, Pergam SA, Limaye AP, Englund J, et al
    How Immunocompromised Hosts Were Left Behind in the Quest to Control the Covid-19 Pandemic.
    Clin Infect Dis. 2024 Jun 3:ciae308. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2024
91. WOLFE DN, Arangies E, David GL, Armstrong B, et al
    Development of Next-Generation COVID-19 Vaccines: BARDA Supported Phase 2b Study Designs.
    Clin Infect Dis. 2024 May 28:ciae286. doi: 10.1093.
    PubMed     Abstract available
    
    
    
92. HILL JA, Martens MJ, Young JH, Bhavsar K, et al
    SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study.
    Clin Infect Dis. 2024 May 27:ciae291. doi: 10.1093.
    PubMed     Abstract available
    
    
    
93. JORGENSEN SCJ, Brown K, Clarke AE, Schwartz KL, et al
    The Effect of COVID-19 Vaccination on Outpatient Antibiotic Prescribing in Older Adults: A Self-Controlled Risk-Interval Study.
    Clin Infect Dis. 2024 May 3:ciae182. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2024
94. 
    Correction to: Impact of Seasonal Coronavirus Antibodies on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Responses in Solid Organ Transplant Recipients.
    Clin Infect Dis. 2024 Apr 30:ciae164. doi: 10.1093.
    PubMed    
    
    
    
95. MWESIGWA B, Sawe F, Oyieko J, Mwakisisile J, et al
    Safety and Immunogenicity of Accelerated Heterologous Two-dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa.
    Clin Infect Dis. 2024 Apr 24:ciae215. doi: 10.1093.
    PubMed     Abstract available
    
    
    
96. HASAN T, Lynch M, King C, Wehbe C, et al
    Vaccine-Preventable Disease Outbreaks among Healthcare Workers: A Scoping Review.
    Clin Infect Dis. 2024 Apr 17:ciae209. doi: 10.1093.
    PubMed     Abstract available
    
    
    
97. 
    Correction to: Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine Recipients.
    Clin Infect Dis. 2024 Apr 15:ciae165. doi: 10.1093.
    PubMed    
    
    
    
98. SHERMAN A, Tuan J, Cantos VD, Adeyiga O, et al
    COVID-19 vaccine efficacy in participants with weakened immune systems from four randomized-controlled trials.
    Clin Infect Dis. 2024 Apr 10:ciae192. doi: 10.1093.
    PubMed     Abstract available
    
    
    
99. FAHERTY EAG, Holly T, Ogale YP, Spencer H, et al
    Investigation of an mpox outbreak affecting many vaccinated persons in Chicago, IL-March 2023-June 2023.
    Clin Infect Dis. 2024 Apr 3:ciae181. doi: 10.1093.
    PubMed     Abstract available
    
    
    
100. SU WJ, Chen HL, Chen SF, Liu YL, et al
     Optimization of Mother-to-Child Hepatitis B Virus Prevention Program: Integration of Maternal Screening and Infant Post-vaccination Serologic Testing.
     Clin Infect Dis. 2024 Apr 2:ciae176. doi: 10.1093.
     PubMed     Abstract available
     
     
     March 2024
101. ROSTAD CA, Atmar RL, Walter EB, Frey S, et al
     A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered with and without AS03 Adjuvant in Healthy US
     Clin Infect Dis. 2024 Mar 27:ciae173. doi: 10.1093.
     PubMed     Abstract available
     
     
     
102. PINEDA-PENA AC, Jiang Q, Petit C, Korejwo-Peyramond J, et al
     Immunogenicity and Safety of a Purified Vero Rabies Vaccine - Serum Free, Compared With Two Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized Controlled Phase III Trial.
     Clin Infect Dis. 2024 Mar 13:ciae137. doi: 10.1093.
     PubMed     Abstract available
     
     
     
103. SHRESTHA NK, Burke PC, Nowacki AS, Gordon SM, et al
     Effectiveness of the 2023-2024 Formulation of the Coronavirus Disease 2019 mRNA Vaccine.
     Clin Infect Dis. 2024 Mar 11:ciae132. doi: 10.1093.
     PubMed     Abstract available
     
     
     
104. ROMINE JK, Li H, Coughlin MM, Jones JM, et al
     Hybrid immunity and SARS-CoV-2 antibodies: results of the HEROES-RECOVER prospective cohort study.
     Clin Infect Dis. 2024 Mar 11:ciae130. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2024
105. SHAH MM, Joyce B, Plumb ID, Sahakian S, et al
     Combined protection of vaccination and nirmatrelvir-ritonavir against hospitalization in adults with COVID-19.
     Clin Infect Dis. 2024 Feb 27:ciae105. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2023
106. THOMAS LD, Batarseh E, Hamdan L, Haddadin Z, et al
     Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients.
     Clin Infect Dis. 2023;77:1723-1732.
     PubMed     Abstract available
     
     
     
107. RYBAK A, Assad Z, Levy C, Bonarcorsi S, et al
     Age-specific resurgence in invasive pneumococcal disease incidence in the COVID-19 pandemic era and its association with respiratory virus and pneumococcal carriage dynamics: a time series analysis.
     Clin Infect Dis. 2023 Dec 6:ciad746. doi: 10.1093.
     PubMed     Abstract available
     
     
     November 2023
108. USDAN L, Patel S, Rodriguez H, Xu X, et al
     A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in >/=12-Year-Olds.
     Clin Infect Dis. 2023 Nov 28:ciad718. doi: 10.1093.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.